Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials

Eric Plennevaux, Annick Moureau, José L Arredondo-García, Luis Villar, Punnee Pitisuttithum, Ngoc H Tran, Matthew Bonaparte, Danaya Chansinghakul, Diana L Coronel, Maïna L'Azou, R Leon Ochiai, Myew-Ling Toh, Fernando Noriega, Alain Bouckenooghe, Eric Plennevaux, Annick Moureau, José L Arredondo-García, Luis Villar, Punnee Pitisuttithum, Ngoc H Tran, Matthew Bonaparte, Danaya Chansinghakul, Diana L Coronel, Maïna L'Azou, R Leon Ochiai, Myew-Ling Toh, Fernando Noriega, Alain Bouckenooghe

Abstract

Background: We previously reported that vaccination with the tetravalent dengue vaccine (CYD-TDV; Dengvaxia) may bias the diagnosis of dengue based on immunoglobulin M (IgM) and immunoglobulin G (IgG) assessments.

Methods: We undertook a post hoc pooled analysis of febrile episodes that occurred during the active surveillance phase (the 25 months after the first study injection) of 2 pivotal phase III, placebo-controlled CYD-TDV efficacy studies that involved ≥31000 children aged 2-16 years across 10 countries in Asia and Latin America. Virologically confirmed dengue (VCD) episode was defined with a positive test for dengue nonstructural protein 1 antigen or dengue polymerase chain reaction. Probable dengue episode was serologically defined as (1) IgM-positive acute- or convalescent-phase sample, or (2) IgG-positive acute-phase sample and ≥4-fold IgG increase between acute- and convalescent-phase samples.

Results: There were 1284 VCD episodes (575 and 709 in the CYD-TDV and placebo groups, respectively) and 17673 other febrile episodes (11668 and 6005, respectively). Compared with VCD, the sensitivity and specificity of probable dengue definition were 93.1% and 77.2%, respectively. Overall positive and negative predictive values were 22.9% and 99.5%, respectively, reflecting the much lower probability of correctly confirming probable dengue in a population including a vaccinated cohort. Vaccination-induced bias toward false-positive diagnosis was more pronounced among individuals seronegative at baseline.

Conclusions: Caution will be required when interpreting IgM and IgG data obtained during routine surveillance in those vaccinated with CYD-TDV. There is an urgent need for new practical, dengue-specific diagnostic algorithms now that CYD-TDV is approved in a number of dengue-endemic countries.

Clinical trials registration: NCT01373281 and NCT01374516.

Figures

Figure 1.
Figure 1.
Proportion of immunoglobulin M–positive (acute or convalescent) participants in virologically confirmed dengue (VCD) cases and other febrile cases without virological evidence of dengue according to baseline dengue serostatus, seropositive/immune (A) or seronegative/nonimmune (B) at baseline, and proportion of acute immunoglobulin G–positive participants according to baseline dengue serostatus, seropositive/immune (C) and seronegative/nonimmune (D) at baseline. VCD episodes were defined with a positive test for dengue nonstructural protein 1 (NS1) antigen or dengue polymerase chain reaction. Baseline dengue serostatus was defined by plaque reduction neutralization test (PRNT50); seropositive was defined as a titer ≥10 1/dil for at least 1 serotype and seronegative as a titer <10 1/dil for any serotype.
Figure 2.
Figure 2.
Change in relative immunoglobulin M (A) and immunoglobulin G (B) levels between acute (blue circle) and convalescent (red line) samples in virologically confirmed dengue (VCD) episodes and other febrile episodes without virological evidence of dengue, according to the dengue baseline serostatus (immune or nonimmune) and the treatment received (CYD-TDV or placebo control). VCD episodes were defined with a positive test for dengue nonstructural protein 1 (NS1) antigen or dengue polymerase chain reaction. Abbreviations: ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; IgM, immunoglobulin M; VCD, virologically confirmed dengue.
Figure 3.
Figure 3.
Immunoglobulin M (IgM)/immunoglobulin G (IgG) ratio distribution (on convalescent samples) in participants with virologically confirmed dengue (VCD) according to the treatment received and the baseline dengue serostatus: seropositive/immune (A) and seronegative/nonimmune (B). VCD episodes were defined with a positive test for dengue nonstructural protein 1 (NS1) antigen or dengue polymerase chain reaction. Baseline dengue serostatus was defined by plaque reduction neutralization test (PRNT50); seropositive was defined as a titer ≥10 1/dil for at least 1 serotype and seronegative as a titer <10 1/dil for any serotype.
Figure 4.
Figure 4.
Immunoglobulin M (IgM)/immunoglobulin G (IgG) ratio distribution (on convalescent samples) in participants with other febrile episodes (no virological evidence of dengue) according to the treatment received and the baseline dengue serostatus: seropositive/immune (A) and seronegative/nonimmune (B). Baseline dengue serostatus was defined by plaque reduction neutralization test (PRNT50) assay; seropositive was defined as a titer ≥10 1/dil for at least 1 serotype and seronegative as a titer <10 1/dil for any serotype.

References

    1. World Health Organization. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated) Available at: . Accessed 9 December 2016.
    1. Plennevaux E, Sabchareon A, Limkittikul K et al. . Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: utility for efficacy evaluation and impact of future vaccine introduction. Vaccine 2016; 34:2707–12.
    1. Sabchareon A, Wallace D, Sirivichayakul C et al. . Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559–67.
    1. L’Azou M, Moureau A, Sarti E et al. ; CYD15 Primary Study Group Symptomatic dengue in children in 10 Asian and Latin American countries. N Engl J Med 2016; 374:1155–66.
    1. Capeding MR, Tran NH, Hadinegoro SR et al. ; CYD14 Study Group Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358–65.
    1. Villar L, Dayan GH, Arredondo-García JL et al. ; CYD15 Study Group Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113–23.
    1. Boaz M, Janosczyk H, Garg S et al. . Virological confirmation of suspected dengue in a phase 2 Latin American vaccine trial: implications for vaccine efficacy evaluation. Trials Vaccinol 2014; 3: 127–33.
    1. World Health Organization. Guidelines for the clinical evaluation of dengue vaccines in endemic areas 2008. Available at: . Accessed 22 March 2017.
    1. World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control 2009. Available at: . Accessed 22 March 2017.
    1. Shu PY, Chen LK, Chang SF et al. . Comparison of capture immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent assay (ELISA) and nonstructural protein NS1 serotype-specific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin Diagn Lab Immunol 2003; 10:622–30.
    1. Cucunawangsih , Lugito NP, Kurniawan A. Immunoglobulin G (IgG) to IgM ratio in secondary adult dengue infection using samples from early days of symptoms onset. BMC Infect Dis 2015; 15: 276.
    1. Prince HE, Yeh C, Lapé-Nixon M. Utility of IgM/IgG ratio and IgG avidity for distinguishing primary and secondary dengue virus infections using sera collected more than 30 days after disease onset. Clin Vaccine Immunol 2011; 18:1951–6.
    1. Innis BL, Nisalak A, Nimmannitya S et al. . An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 1989; 40:418–27.
    1. Karyana IPG, Santoso H, Arhana BNP. The value of IgG to IgM ratio in predicting secondary dengue infection. Paediatrica Indonesiana 2006; 46:113–7.
    1. Peeling RW, Artsob H, Pelegrino JL et al. . Evaluation of diagnostic tests: dengue. Nat Rev Microbiol 2010; 8:S30–8.
    1. Olivera-Botello G, Coudeville L, Fanouillere K et al. ; CYD-TDV Vaccine Trial Group Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2-16 years in Asia and Latin America. J Infect Dis 2016; 214:994–1000.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren